Fact CheckerSign in

NCT07391137Active, not recruiting

CRUCIAL-R Study : Cruciferous Vegetables Dietary Regimen in NMIBC

The Effects of a Dietary Regimen Characterized by High Consumption of Cruciferous Vegetables on Recurrence-free Survival in Patients With Intermediate, High and Very High-risk Non-Muscle Invasive Bladder Cancer: a Randomized Trial

Source: ClinicalTrials.gov · Last updated 9 Feb 2026

Brief summary (registry, in English)

Emerging evidence highlights the importance of nutrition in modulating cancer-related pathways, suggesting that specific dietary patterns and food choices may influence cancer risk. A protective role has been suggested for high consumption of vegetables, non-saturated fat oil (Mediterranean diet), fruits, and flavonoids \[10-13\]. In contrast, a diet rich in saturated fats and meat has been linked to an increased risk of BC \[14,15\]. Particularly, the consumption of vegetables of the Cruciferae family, such as broccoli, cauliflower, brussels sprouts, cabbage, kale, turnips, and others, has gathered attention for their potential protective effects due to their bioactive compounds: Isothiocyanates (ITCs). Dietary ITCs are a group of phytochemicals with multifaceted anticancer mechanisms primarily derived from cruciferous vegetables (CV) as glucosinolates and converted to ITCs by the action of the enzyme myrosinase \[16\]. Organic ITCs, particularly allyl isothiocyanate (AITC), benzyl isothiocyanate (BITC), phenethyl isothiocyanate (PEITC), and sulforaphane (SF), are among the most extensively studied cancer chemopreventive agents. Several mechanisms for ITCs in protection against carcinogenesis have been proposed, which include inhibition of carcinogen activation and promotion of detoxification, induction of cell cycle arrest and activation of apoptosis, inhibition of cancer cell invasion, modulation of the tumor microenvironment, inhibition of self-renewal of stem cells, rearrangement of energy metabolism and regulation of microbial homeostasis \[17-22\]. Aims Primary Objective • To evaluate the effect, in terms of recurrence-free survival (RFS) at 1 year, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, or Very High-grade Non-Muscle Invasive Bladder Cancer treated with BCG (defined as the standard of care - SOC). Secondary Objectives * To evaluate the effect, in terms of time to recurrence, of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer. * To evaluate the effect, in terms of recurrence-free survival (RFS), of a dietary regimen characterized by high consumption of the Cruciferae family vegetables versus no dietary regimen in patients with Intermediate, High, and Very High-grade Non-Muscle Invasive Bladder Cancer with prior recurrence ≤1/yr and \<4 tumors (according to 2016 EORTC risk stratification for patients treated with maintenance BCG). * To evaluate the impact of high Cruciferous vegetable consumption on urinary ITC levels. * To evaluate the impact of high Cruciferous vegetable consumption on quality of life (QoL).

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
250 (estimated)
First submitted
15 Apr 2025
Start date
17 Oct 2025
Primary completion date
1 Nov 2026
Lead sponsor
S. Andrea Hospital
NCT number
NCT07391137

What you commit to

  • Study type: Interventional
  • Planned participants: 250
  • From 17 Oct 2025 to the primary completion date, 1 Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Concomitant Urothelial Bladder Cancer in the Upper-Urinary Tract
  • Prostate or bladder radiotherapy
  • Warfarin therapy

Other illness

  • Low-Risk Non-Muscle Invasive Bladder Cancer
  • Muscle Invasive Bladder Cancer
  • Urinary tract infection
  • Other ongoing oncological diseases
  • Persistent disease (defined as residual disease detected within three months after TURB or at first cystoscopy)
  • Specific dietary restrictions such as a vegetarian diet, celiac disease, or lactose intolerance
  • Chronic Kidney Disease
  • Chronic inflammatory diseases such as Crohn's disease or ulcerative colitis
  • History of gastric resection
  • Thyroid disorders

Lab values

  • Hepatic disorders such as cirrhosis or ALT/AST levels three times above the upper normal limit

Age

  • Life expectancy \< 5 years

Other

  • WHO performance status 3 or 4
  • Variant histology
  • Chronic urinary retention or indwelling catheters
  • Active oncological treatments in the past 12 months

Who the study is looking for

  • Histologically confirmed Non-Muscle Invasive Bladder Cancer of Intermediate, High, or Very High risk according to the 2021 EAU NMIBC scoring model.
  • Age ≥ 18

Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
S.Andrea Hospital of Rome
Coordinator of this site? Confirm its status
RomeItalyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.